| 1 |
27729187 | Eeyarestatin I derivatives with improved aqueous solubility. | 2016 Nov 1 |
1 |
| 2 |
25406314 | Combining valosin-containing protein (VCP) inhibition and suberanilohydroxamic acid (SAHA) treatment additively enhances the folding, trafficking, and function of epilepsy-associated γ-aminobutyric acid, type A (GABAA) receptors. | 2015 Jan 2 |
1 |
| 3 |
25970786 | Regulation of VCP/p97 demonstrates the critical balance between cell death and epithelial-mesenchymal transition (EMT) downstream of ER stress. | 2015 Jul 10 |
1 |
| 4 |
21124757 | The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membrane-binding domain and a p97/VCP inhibitory group. | 2010 Nov 12 |
2 |